Feedback / Questions
quetmolimab (E6011) - Eisai
Eisai: Scientific Day
(Eisai)
-
Jul 2, 2016 -
"Phase 1b E6011 study: Efficacy signals in Crohn's disease"; "Clinical Response & Remission at week 12: High remission rate at 10 mg/kg in Crohn's disease"
P1 data
•
Inflammatory Bowel Disease
http://www.eisai.com/pdf/eir/emat/e4523_160629.pdf
Jul 2, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious